Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Invasive fungal infection (IFI) following liver transplant is associated with significant morbidity and mortality. Antifungal prophylaxis is rational for liver transplant patients at high IFI risk. METHODS: In this open-label, noninferiority study, patients were randomized 1:1 to receive intravenous micafungin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant. The primary endpoint was clinical success (absence of a proven/probable IFI and no need for additional antifungals) at end of prophylaxis (EOP). Noninferiority (10% margin) of micafungin vs standard care was assessed in the per protocol and full analysis sets. Safety assessments included adverse events and liver and kidney function tests. RESULTS: The full analysis set comprised 344 patients (172 micafungin; 172 standard care). Mean age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score ≥20. At EOP (mean treatment duration, 17 days), clinical success was 98.6% for micafungin and 99.3% for standard care (Δ standard care - micafungin [95% confidence interval], 0.7% [-2.7% to 4.4%]) in the per protocol set and 96.5% and 93.6%, respectively (-2.9% [-8.0% to 1.9%]), in the full analysis set. Incidences of drug-related adverse events for micafungin and standard care were 11.6% and 16.3%, leading to discontinuation in 6.4% and 11.6% of cases, respectively. At EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standard care-treated patients. CONCLUSIONS: Micafungin was noninferior to standard care as antifungal prophylaxis in liver transplant patients at high risk for IFI. Adverse event profiles and liver function at EOP were similar, although kidney function was better with micafungin. CLINICAL TRIALS REGISTRATION: NCT01058174.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 2×
“according to the EORTC/MSG definitions [26], was confirmed by an Independent Data Review Board (IDRB).”
BackgroundMethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“the case of fluconazole, to these agents [17-19, 31].”
BackgroundCONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“antifungal prophylaxis in liver transplant recipients with multiple IFI risk factors [15-17].”
BackgroundPappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“The echinocandins have demonstrated broad efficacy against Candida species, have low toxicity, few drug–drug interactions and are established first-line treatments for invasive candidiasis [22-24].”
BackgroundAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“glabrata has emerged [40].”
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Cited by
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationHusain, S., & Camargo, J. F. (2019) · Clinical Transplantation · doi:10.1111/ctr.13544 · Cited by 302
Kim, D.-S., Yoon, Y.-I., Kim, B. K., Choudhury, A., Kulkarni, A., Park, J. Y., Kim, J., Sinn, D. H., Joo, D. J., Choi, Y., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10629-3 · Cited by 47
Lum, L., Lee, A., Vu, M., Strasser, S., & Davis, R. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13361 · Cited by 22
Metadata
- Authors
- Saliba, F., Pascher, A., Cointault, O., Laterre, P.-F., Cervera, C., De Waele, J. J., Cillo, U., Langer, R. M., Lugano, M., Göran-Ericzon, B., Phillips, S., Tweddle, L., Karas, A., Brown, M., Fischer, L., for the TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators, Pratschke, J., Decruyenaere, J., De Waele, J. J., Laterre, P.-F., Moreno, C., Michielsen, P., Cointault, O., Fischer, L., Neuhaus, P., Pascher, A., Schemmer, P., Cervera, C., Varo, E., Montejo, M., Bouza, E., Blanes, M., De La Torre, J., Fortun, J., Saliba, F., Rostaing, L., Paugam-Burtz, C., Eyraud, D., Shah, T., Heaton, N., Langer, R. M., McCormick, A., Cillo, U., Salizzoni, M., Lugano, M., De Gasperi, A., Tomé, L., Daniel, J., Popescu, I., Moysyuk, Y. G., Chzhao, A. V., Zagaynov, V. E., & Ericzon, B.-G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-17
- Volume
- 60
- Issue
- 7
- Pages
- 997-1006
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2132994229
- Cited by
- 82
- References
- 12
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients. https://app.cochat.ai/papers/10.1093/cid/ciu1128
- The paper
- Saliba, F., Pascher, A., Cointault, O., Laterre, P.-F., Cervera, C., De Waele, J. J., Cillo, U., Langer, R. M., Lugano, M., Göran-Ericzon, B., Phillips, S., Tweddle, L., Karas, A., Brown, M., Fischer, L., for the TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators, Pratschke, J., Decruyenaere, J., De Waele, J. J., . . . Ericzon, B.-G. (2015). Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciu1128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.